Enhancing the Pharmacokinetic Profile of Protein-based Drugs

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: W911NF-13-C-0033
Agency Tracking Number: C122-101-0073
Amount: $99,999.00
Phase: Phase I
Program: SBIR
Awards Year: 2013
Solitcitation Year: 2012
Solitcitation Topic Code: CBD12-101
Solitcitation Number: 2012.2
Small Business Information
Extend Biosciences Inc.
48 Russell St. #3, Cambridge, MA, -
Duns: 963416420
Hubzone Owned: N
Woman Owned: Y
Socially and Economically Disadvantaged: N
Principal Investigator
 Laura Hales
 Chief Scientific Officer
 (732) 599-8581
 lhales@extendbio.com
Business Contact
 Tarik Soliman
Title: Chief Executive Officer
Phone: (732) 599-8580
Email: tsoliman@extendbio.com
Research Institution
 Stub
Abstract
Many protein-based drugs have limited efficacy due to a short half-life or require intravenous delivery because of low bioavailability when given subcutaneously. Extend Biosciences is developing proprietary carrier molecules that will allow proteins to access a transport pathway for efficient delivery to the vascular space and then maintain a sustained presence in circulation. This would be of particular importance in the development of longer-lasting versions of bioscavenger proteins that could then be delivered subcutaneously and become bioavailable within minutes of administration. In this project, one of Extend Biosciences"carrier molecules will be conjugated to two bioscavenger proteins of interest to the military as further proof-of-concept for the technology. The modified bioscavengers will be assayed in vitro to ensure that the carrier molecule does not disrupt functional activity. Following success in Phase I, the Phase II studies would test the modified bioscavengers for their improved half-life and bioavailability when delivered subcutaneously in an appropriate animal model, and test whether the modified protein induces toxicity or an immune response. This project will demonstrate the feasibility of improving the half-life and bioavailability of bioscavenger proteins that could be applied to numerous other protein-based drugs including those used in Chemical and Biological Defense treatments.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government